Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy

• Main Authors: Cruz E, Kayser V
• Format: Article
• Language: English
• Published: Dove Medical Press 2019-05-01
• Series: Biologics : Targets & Therapy
• Subjects: antibody therapy; treatment resistance; antibody-drug conjugates; immune checkpoint inhibitors; nanoparticle delivery vehicles
• Online Access: https://www.dovepress.com/monoclonal-antibody-therapy-of-solid-tumors-clinical-limitations-and-n-peer-reviewed-article-BTT

Esteban Cruz, Veysel KayserSchool of Pharmacy, The University of Sydney, Sydney, NSW, AustraliaAbstract: Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of a wide range of solid tumors. The targeted nature of these biotherapeutics has improved treatment outcomes by offering enhanced specificity to reduce severe side effects experienced with conventional chemotherapy. Notwithstanding, poor tumor tissue penetration and the heterogeneous distribution achieved therein are prominent drawbacks that hamper the clinical efficacy of therapeutic antibodies. Failure to deliver efficacious doses throughout the tumor can lead to treatment failure and the development of acquired resistance mechanisms. Comprehending the morphological and physiological characteristics of solid tumors and their microenvironment that affect tumor penetration and distribution is a key requirement to improve clinical outcomes and realize the full potential of monoclonal antibodies in oncology. This review summarizes the essential architectural characteristics of solid tumors that obstruct macromolecule penetration into the targeted tissue following systemic delivery. It further describes mechanisms of resistance elucidated for blockbuster antibodies for which extensive clinical data exists, as a way to illustrate various modes in which cancer cells can overcome the anticancer activity of therapeutic antibodies. Thereafter, it describes novel strategies designed to improve clinical outcomes of mAbs by increasing potency and/or improving tumor delivery; focusing on the recent clinical success and growing clinical pipeline of antibody-drug conjugates, immune checkpoint inhibitors and nanoparticle-based delivery systems.Keywords: antibody therapy, treatment resistance, antibody–drug conjugates, immune checkpoint inhibitors, nanoparticle delivery vehicles